GE Healthcare Life Sciences has launched a prefabricated, modular bioprocessing facility designed for the manufacture of viral vector-based therapeutics.
A new vaccine manufacturing facility in Toronto, Canada will boast single-use tech and closed continuous process to help improve productivity and performance, Sanofi says.
Demand for a protein produced from a marine mollusk used as a carrier molecule in therapeutic vaccines has driven Stellar Biotech to expand a facility in LA.
Vendors can help address technology gaps but industry must look to collaborations and internal development to create fully continuous bioprocesses, says MilliporeSigma.
“We need Big Pharma and we are getting Big Pharma,” says Dyadic
Dyadic International says a string of deals shows biopharma is beginning to embrace its low-cost and high-yielding – yet commercially unproven – fungus-based expression platform.
Novartis says the manufacturing method for Regeneron’s wet macular degeneration drug Eylea (aflibercept) infringes on its Lucentis (ranibizumab) patents.
The CMO says adding the single-use offering from ABEC will make the newly opened biomanufacturing site in China comparable to stainless steel for commercial mAb production.
Egg adaptation is the biggest culprit in this year’s poor flu vaccine efficacy says Novavax, a firm developing a product based on recombinant protein nanoparticles.
Compugen has selected Selexis’ SUREtechnology cell expression platform to generate high-performance research cell banks (RCBs) and support its antibody pipeline.
